Focal liver lesions: SPIO-, gadolinium-, and ferucarbotran-enhanced dynamic T1-weighted and delayed T2-weighted MR imaging in rabbits

Tailored Magnetic Multicore Nanoparticles for Use as Blood Pool MPI Tracers

For the preclinical development of magnetic particle imaging (MPI) in general, and the exploration of possible new clinical applications of MPI in particular, tailored MPI tracers with surface properties optimized for the intended use are needed. Here we present the synthesis of magnetic multicore particles (MCPs) modified with polyethylene glycol (PEG) for use as blood pool MPI tracers. To achieve the stealth effect the carboxylic groups of the parent MCP were activated and coupled with pegylated amines (mPEG-amines) with different PEG-chain lengths from 2 to 20 kDa. The resulting MCP-PEG variants with PEG-chain lengths of 10 kDa (MCP-PEG10K after one pegylation step and MCP-PEG10K2 after a second pegylation step) formed stable dispersions and showed strong evidence of a successful reaction of MCP and MCP-PEG10K with mPEG-amine with 10 kDa, while maintaining their magnetic properties. In rats, the mean blood half-lives, surprisingly, were 2 and 62 min, respectively, and therefore, for MCP-PEG10K2, dramatically extended compared to the parent MCP, presumably due to the higher PEG density on the particle surface, which may lead to a lower phagocytosis rate. Because of their significantly extended blood half-life, MCP-PEG10K2 are very promising as blood pool tracers for future in vivo cardiovascular MPI.

Novel magnetic multicore nanoparticles designed for MPI and other biomedical applications: From synthesis to first in vivo studies

Synthesis of novel magnetic multicore particles (MCP) in the nano range, involves alkaline precipitation of iron(II) chloride in the presence of atmospheric oxygen. This step yields green rust, which is oxidized to obtain magnetic nanoparticles, which probably consist of a magnetite/maghemite mixed-phase. Final growth and annealing at 90°C in the presence of a large excess of carboxymethyl dextran gives MCP very promising magnetic properties for magnetic particle imaging (MPI), an emerging medical imaging modality, and magnetic resonance imaging (MRI). The magnetic nanoparticles are biocompatible and thus potential candidates for future biomedical applications such as cardiovascular imaging, sentinel lymph node mapping in cancer patients, and stem cell tracking. The new MCP that we introduce here have three times higher magnetic particle spectroscopy performance at lower and middle harmonics and five times higher MPS signal strength at higher harmonics compared with Resovist®. In addition, the new MCP have also an improved in vivo MPI performance compared to Resovist®, and we here report the first in vivo MPI investigation of this new generation of magnetic nanoparticles.

The design of a multifunctional dendrimer-based nanoplatform for targeted dual mode SPECT/MR imaging of tumors

A multifunctional dendrimer-based nanoplatform labeled with ^99mTc can be synthesized for targeted SPECT/MR dual mode imaging of tumors.

Synthesis methods to prepare single- and multi-core iron oxide nanoparticles for biomedical applications

We review and classify synthetic routes to either single-core or multi-core iron oxide nanoparticles for biomedical applications.

Determination of liver-specific r2 * of a highly monodisperse USPIO by (59) Fe iron core-labeling in mice at 3 T MRI

Accurate determination of tissue concentration of ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) using T2 * MR relaxometry is still challenging. We present a reliable quantification method for local USPIO amount with the estimation of the liver specific relaxivity r2 * using monodisperse (59) Fe-core-labeled USPIO ((59) FeUSPIO). Dynamic and relaxometric in vivo characteristics of unlabeled monodisperse USPIO were determined in MRI at 3 T. The in vivo MR studies were performed for liver tissue with (59) FeUSPIO using iron dosages of 9 (n = 3), 18 (n = 2) and 27 (n = 3) µmol Fe kg(-1) body weight. The R2 * of the liver before and after USPIO injection (∆R2 *) was measured and correlated with (59) Fe activity measurements of excised organs by a whole body radioactivity counter (HAMCO) to define the dependency of ∆R2 * and (59) FeUSPIO liver concentration and calculate the r2 * of (59) FeUSPIO for the liver. Ultrastructural analysis of liver uptake was performed by histology and transmission electron microscopy. ∆R2 * of the liver revealed a dosage-dependent accumulation of (59) FeUSPIO with a percentage uptake of 70-88% of the injection dose. Hepatic ∆R2 * showed a dose-dependent linear correlation to (59) FeUSPIO activity measurements (r = 0.92) and an r2 * in the liver of 481 ± 74.9 mm(-1) s(-1) in comparison to an in vitro r2 * of 60.5 ± 3.3 mm(-1) s(-1) . Our results indicate that core-labeled (59) FeUSPIO can be used to quantify the local amount of USPIO and to estimate the liver-specific relaxivity r2 *.

Mn₃[Co(CN)₆]₂@SiO₂ core-shell nanocubes: novel bimodal contrast agents for MRI and optical imaging

Nanoprobes with dual modal imaging of magnetic resonance imaging (MRI) and two-photon fluorescence (TPF) can serve as promising platforms for clinical diagnosis. A wide range of molecules and nanoparticles have been investigated as agents for contrast enhanced MRI and fluorescence imaging in cancer diagnosis. However, a single material with dual modal imaging of MRI and TPF is rarely reported. We found that Mn₃[Co(CN)₆]₂@SiO₂ nanocubes can serve as agents for both T₁- and T₂-weighted MRI, and TPF imaging. The nanocubes coated with silica to form Mn₃[Co(CN)₆]₂@SiO₂ core-shell nanocubes were readily internalized by cells without showing cytotoxicity. In vitro tests, the core-shell nanocubes display relatively high longitudinal (r₁) and transverse (r₂) relaxivities, they also manifest a remarkable T₁ and T₂ contrast effects at in-vivo imaging of internal organs in Mice. Moreover, the core-shell nanocubes could offer high-resolution cell fluorescence imaging by two-photon excitation (720 nm) or by conventional fluorescence with 403- or 488-nm excitation.

Magnetic iron oxide nanoparticles for biomedical applications

Due to their high magnetization, superparamagnetic iron oxide nanoparticles induce an important decrease in the transverse relaxation of water protons and are, therefore, very efficient negative MRI contrast agents. The knowledge and control of the chemical and physical characteristics of nanoparticles are of great importance. The choice of the synthesis method (microemulsions, sol-gel synthesis, laser pyrolysis, sonochemical synthesis or coprecipitation) determines the magnetic nanoparticle's size and shape, as well as its size distribution and surface chemistry. Nanoparticles can be used for numerous in vivo applications, such as MRI contrast enhancement and hyperthermia drug delivery. New developments focus on targeting through molecular imaging and cell tracking.

Magnetic resonance enhancement pattern and diagnostic accuracy of gadofluorine M in a rabbit VX2 tumor model: Comparison with gadopentetate dimeglumine

OBJECTIVE

The purpose of this study was to evaluate the enhancement pattern and the diagnostic accuracy of gadofluorine M in comparison with gadopentetate dimeglumine in a rabbit VX2 tumor model.

MATERIALS AND METHODS

Thirteen rabbits with experimentally induced VX2 carcinomas in the thighs underwent sequential T1-weighted enhancement MR imaging using a 3.0T MR imager, first with gadopentetate dimeglumine, and then 24 (n=4) or 4h (n=9) later with gadofluorine M. In 4 rabbits with 13 tumors, the time-percentage enhancement (PE; i.e., percentage of signal intensity increase) curve was obtained for up to 24h for each contrast agent. In 9 rabbits with 49 tumors (random numbers of VX2 tumors were inoculated at random sites in the thigh), 3 readers unaware of the histopathologic results interpreted the MR images and determined the number and conspicuity level of the detected tumors. The reference standard was the histopathology of the specimen.

RESULTS

The time-to-peak PE for gadopentetate dimeglumine was 1min and gadopentetate dimeglumine showed a rapid washout pattern. The time-to-peak PE for gadofluorine M was 30min and gadofluorine M showed a plateau enhancement pattern for up to 24h. The peak PE of gadofluorine M was approximately twice that of the same dose of gadopentetate dimeglumine (108.2±14.8 vs. 51.5±24.0). The sensitivities for detecting VX2 tumors by 3 readers were 89.8% (44/49), 85.7% (42/49), and 95.9% (47/49) for gadopentetate dimeglumine-enhanced MR imaging, and 87.8% (43/49), 89.8% (44/49), and 89.8% (44/49) for gadofluorine M-enhanced MR imaging. No significant differences in the sensitivities existed between the two contrast agents for any reader. However, the conspicuity level of tumors was superior with gadofluorine M-enhanced MR imaging for two readers and similar for the other reader.

CONCLUSION

Gadofluorine M showed strong and plateau enhancement of tumors for up to 24h. In the reader study, gadofluorine M showed better conspicuity for VX2 tumors than gadopentetate dimeglumine, but had a similar sensitivity.

Enabling individualized therapy through nanotechnology

Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of 'losing sight of the forest for the trees'. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80% of the patient population. The emergence of "-omic" technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon "-omic" technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology "snapshot" of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to "self-correct" in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.

Superparamagnetic iron oxide nanoparticle-labeled cells as an effective vehicle for tracking the GFP gene marker using magnetic resonance imaging

BACKGROUND

Detection of a gene using magnetic resonance imaging (MRI) is hindered by the magnetic resonance (MR) targeting gene technique. Therefore it may be advantageous to image gene-expressing cells labeled with superparamagnetic iron oxide (SPIO) nanoparticles by MRI.

METHODS

The GFP-R3230Ac (GFP) cell line was incubated for 24 h using SPIO nanoparticles at a concentration of 20 microg Fe/mL. Cell samples were prepared for iron content analysis and cell function evaluation. The labeled cells were imaged using fluorescent microscopy and MRI.

RESULTS

SPIO was used to label GFP cells effectively, with no effects on cell function and GFP expression. Iron-loaded GFP cells were successfully imaged with both fluorescent microscopy and T2*-weighted MRI. Prussian blue staining showed intracellular iron accumulation in the cells. All cells were labeled (100% labeling efficiency). The average iron content per cell was 4.75+/-0.11 pg Fe/cell (P<0.05 versus control).

DISCUSSION

This study demonstrates that the GFP expression of cells is not altered by the SPIO labeling process. SPIO-labeled GFP cells can be visualized by MRI; therefore, GFP, a gene marker, was tracked indirectly with the SPIO-loaded cells using MRI. The technique holds promise for monitoring the temporal and spatial migration of cells with a gene marker and enhancing the understanding of cell- and gene-based therapeutic strategies.

Assessment of the tolerance dose of the hepatic reticulo-endothelial system (RES) after single fraction HDR-irradiation: an in-vivo study employing SSPIO

PURPOSE

To prospectively assess a dose-response relationship for the hepatic reticulo-endothelial system (RES) after small volume single fraction irradiation of liver parenchyma in vivo.

MATERIALS AND METHODS

Twenty-five liver tumors were treated by computed tomography (CT)-guided interstitial brachytherapy. Magnetic resonance imaging (MRI) was performed 1 day before and 3 days, 6, 12 and 24 weeks after therapy. MR-sequences included T2-w Turbo Spin Echo (TSE) enhanced by hepatic RES targeted Standard Superparamagnetic Iron Oxide (SSPIO). All MRI data sets were merged with three dimensional (3D) dosimetry data and evaluated by two radiologists. We estimated the threshold dose for either edema or function loss as the D90. A match-pair analysis was performed with another 25 liver tumors, which were treated the same but had MRI follow-up using the hepatocyte specific MRI contrast media Gadobenate dimeglumine (Gd-BOPTA).

RESULTS

Three days post brachytherapy the D90 for hepatic RES function loss reached the 18.3 Gray (Gy) isosurface (Standard Deviation (SD) 7.7). At 6 weeks, the respective zone had increased significantly to the 12.9 Gy isosurface (SD 4.4). After 12 and 24 weeks, the dysfunction of liver volume decreased significantly to the 15 Gy and 20.4 Gy isosurface respectively (SD 7.1 and 10.0). Comparison to the hepatocyte function loss indicates a higher minimal threshold dose of the hepatic RES.

CONCLUSION

Hepatic RES demonstrated a high regenerative capacity and a higher minimal threshold dose than hepatocytes. Temporary function loss was found from the 13 Gy isosurface.